2025-11-25FDA approves durvalumab for resectable gastric or gastroesophageal junction adenocarcinomaDrugs Imfinzi (durvalumab) · Anti-PD-L1 antibody, fluorouracil · FluoropyrimidineConditionGastrointestinal
2022-10-21FDA approves tremelimumab in combination with durvalumab for unresectable hepatocellular carcinomaTrial HIMALAYADrugs Imjudo (tremelimumab) · Anti-CTLA-4 antibody, durvalumab · Anti-PD-L1 antibodyConditionGastrointestinal
2022-09-02FDA approves durvalumab for locally advanced or metastatic biliary tract cancerTrial TOPAZ-1Drugs Imfinzi (durvalumab) · Anti-PD-L1 antibody, gemcitabine · Pyrimidine analog, cisplatin · Platinum agentConditionGastrointestinal
2020-05-29FDA approves atezolizumab plus bevacizumab for unresectable hepatocellular carcinomaTrial IMbrave150Drugs TECENTRIQ (atezolizumab) · Anti-PD-L1 antibody, AVASTIN (bevacizumab) · Anti-VEGFR antibodyConditionGastrointestinal